Leading researchers and experts in genomics and newborn sequencing representing the U.S., the U.K., Europe, Australia, and the Middle East came together in London at the Royal Institution for the second annual International Conference on Newborn Sequencing (ICoNS) co-hosted with Genomics England to present updates regarding their own research and share future plans. The conference … Continued
At the 2023 International Conference on Newborn Sequencing (ICoNS), Drs. Robert Green and Ingrid Holm, Co-PIs of BabySeq2, share updates on the BabySeq Project.
At the 2023 International Conference on Newborn Sequencing (ICoNS), Dr. Robert Green moderates a panel on the up and downstream ecosystem of newborn sequencing. Panelists include Dr. Vanessa Almendro from Danaher Corp, Dr. Paul Kruszka from GeneDx, and Dr. Jennifer Ibrahim from Sanofi.
Drs. Robert Green and David Bick, Co-Chairs of the International Consortium on Newborn Sequencing, share their introductory remarks at the start of ICoNS’23 in London, UK.
Read about how the second iteration of The BabySeq Project, BabySeq 2.0, is striving to make genome sequencing accessible to a diverse population of newborns at Boston Children’s Hospital and other sites around the country. Ingrid Holm, MD, MPH who co-leads BabySeq 2.0 describes how seeking input from a Community Advisory Board from each participating … Continued
Fashion 4 Development (F4D) in partnership with Human Kind Institute hosted the Third Annual Sustainable Goals Banquet on Monday, September 18th during the 78th Session of the United Nations General Assembly (UNGA). The evening’s theme was ‘Healthier People, Healthier Planet.’ The night’s final award served as a tribute to the late Franca Sozzani, Editor in … Continued
This newsletter highlights the International Conference on Newborn Sequencing (ICoNS) that is just around the corner on October 5-6, 2023 in London, UK. It’s not too late to register! Other G2P updates include media coverage of BabySeq1 publications, a new publication from the Sanford Imagenetics team about pharmacogenomics in primary care, and a blog post … Continued
Each month, the editors of Human Genetics and Genomics Advances interview an early-career researcher who has published work in the journal. This month they featured G2P collaborator Dr. Nina Gold to discuss her paper Phenotypes of undiagnosed adults with actionable OTC and GLA variants.
In this webinar Dr. Green explores the path towards a more personalized and preventive approach to medicine. He draws on insights gained from the MedSeq and BabySeq projects led by the Genomes2People Research Program (G2P).
A recent editorial by The Lancet dives into the debate on universal newborn sequencing. While using genome sequencing as a screening tool for newborns has the potential to offer a great deal of relevant health information, there are certainly ethical issues and other challenges that also need to be addressed. The BabySeq Project is cited … Continued
In this newsletter we’re excited to announce that the Precision Population Health initiative (PPH) is working with the South Central Foundation (SCF) on a new clinical genomic screening program to improve the health of the Alaska Native population. We are also thrilled to share that registration for the Second Annual International Conference on Newborn Sequencing … Continued
“Addressing stark, deeply-rooted racial disparities in healthcare has to be a priority for medical research. PRS might be one tool to improve disease screening and move us beyond race-based medical decision-making and toward more equitable health outcomes.”
During the first session of the National Academies of Sciences, Engineering, and Medicine Workshop entitled Next-Generation Screening – The Promise and Perils of DNA Sequencing of Newborns at Birth, Robert Green participated alongside Ellen Wright Clayton, Crystal Grant, and Mike Hu in a panel discussion moderated by Karen Weck.
During the second session of the National Academies of Sciences, Engineering, and Medicine Workshop entitled Next-Generation Screening – The Promise and Perils of DNA Sequencing of Newborns at Birth, Robert Green shared updates from the BabySeq project in his presentation: Empirical Data on the Path to Universal Newborn Sequencing. Recorded sessions of the entire NASEM workshop … Continued
“The pathogenic or likely pathogenic variants turned up in 13 genes, the team noted, and included variants implicated in Lynch syndrome, breast and ovarian cancer, dilated cardiomyopathy, and other actionable adult-onset or childhood-onset conditions.”
Newborn sequencing experts participated in a full-day workshop examining the utility of DNA sequencing in newborns. The workshop addressed the current state of newborn sequencing as well as relevant expected benefits, harms, and ethical considerations in six sessions. Session I: Opening Remarks & Keynote 9:05 – 9:30 AM: Panel of Discussants (Ellen Wright Clayton, Robert … Continued
“In the future, imagine identifying a risk for a devastating illness in a healthy newborn baby,” Green said. “Imagine then being able to find the biomarkers for the ones who are going to develop the disease and even preventing it. Imagine how thrilling that would be.”
“There are ethicists who say a child should not be used as a genetic canary in a coal mine — that one member of a family should not be used without their consent as the access point for a whole family, but I’d like to challenge that. Look at these mothers. We arguably saved their … Continued
“By screening apparently healthy newborns, entire families were alerted for the first time that dangerous but treatable genetic variants were present,” said corresponding author Robert C. Green, MD, MPH, a physician-scientist at Brigham and Women’s Hospital and professor of genetics at Harvard Medical School, who leads the BabySeq Project. “We were stunned to see that … Continued
“Omics data could herald a revolution in healthcare. The analysis of rich, interconnected and longitudinal multi-omics datasets promises a better understanding of the underlying biology of human health and disease, which in turn could lead to more effective prevention, earlier and more accurate diagnoses, new treatments and better choice of treatments. Despite that promise, only … Continued
On May 18-19, 2023 from 12-4pm (EST), the Newborn Screening Translational Research Network (NBSTRN) hosted a two-day virtual meeting that showcased the important role of advocacy and research in NBS. Robert Green, MD, MPH led a talk on the path to universal newborn sequencing.
Robert Green, MD, MPH will be leading a talk on the path to preventive genomics and universal newborn sequencing in the Pediatric Grand Rounds at The Children’s Hospital at Montefiore.
On May 18-19, 2023 from 12-4pm (EST), the Newborn Screening Translational Research Network (NBSTRN) is hosting a two-day virtual meeting that will showcase the important role of advocacy and research in NBS. Robert Green, MD, MPH will lead a talk on the path to universal newborn sequencing. See the conference link below to learn more and … Continued
Shaye Williams, G2P’s operation coordinator and diversity, equity, and inclusion lead, shares the story of her career transition into genomics research. After being introduced to genetic counseling as a prenatal patient, Shaye pursued an internship with G2P to learn more about the profession.
“Anna Lewis, a Harvard researcher who studies the ethical, legal and social implications of genetics research, said that environmental DNA hadn’t been widely discussed by experts in bioethics. But after the findings from Dr. Duffy and his colleagues, it will be.”
“In a newly released study, nearly nine of 10 experts on rare diseases agreed that sequencing healthy newborns’ DNA to reveal treatable genetic disorders should be available for all infants. At least half of experts also endorsed testing for more than 400 genes as part of such newborn genomic screens. These NCATS-supported study results might … Continued
“While newborns are only screened for about 60 treatable conditions, there are hundreds of genetic disorders that have targeted treatments. Now, a national survey of experts in rare diseases found the vast majority support DNA sequencing in healthy newborns…’It has been a longstanding dream to someday offer DNA sequencing to all newborns in order to … Continued
“Research led by Mass General Hospital for Children suggests that almost 90% of rare disease experts are in favor of newborn genome sequencing for monogenic treatable disorders…’Early identification of infants who are at risk for genetic disorders can be lifesaving and screening has the potential to improve healthcare disparities for affected children,’ said lead author … Continued
Faculty in the Brigham and Women’s Hospital Division of Genetics share updates on their research in the Genetics Faculty Chalk Talk series.
“An overwhelming majority of rare disease experts agree that a genomic sequencing test for monogenic treatable conditions should be available to all newborns, a new survey shows.”
“When 238 rare-disease doctors across the U.S. were surveyed by a research team at Mass General Brigham in Boston, 88% of them agreed that DNA sequencing to screen for certain treatable childhood disorders should be made available to all newborns. The study was published Monday in JAMA Network Open.”
“Findings from a new study led by researchers at Mass General Brigham suggest that rare disease experts are now in favor of more expansive newborn testing. In a study published today in JAMA Network Open, 88 percent of rare disease experts agreed that DNA sequencing to screen for treatable childhood disorders should be made available … Continued
